Is BIOTEC-W1-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIOTEC-W1-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIOTEC-W1-R (THB0.47) is trading above our estimate of fair value (THB0.08)
Significantly Below Fair Value: BIOTEC-W1-R is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIOTEC-W1-R?
Key metric: As BIOTEC-W1-R is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for BIOTEC-W1-R. This is calculated by dividing BIOTEC-W1-R's market cap by their current
earnings.
What is BIOTEC-W1-R's PE Ratio?
PE Ratio
10.8x
Earnings
฿200.96m
Market Cap
฿2.17b
BIOTEC-W1-R key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue
1.1x
Enterprise Value/EBITDA
26x
PEG Ratio
n/a
Price to Earnings Ratio vs Peers
How does BIOTEC-W1-R's PE Ratio compare to its peers?
The above table shows the PE ratio for BIOTEC-W1-R vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Price-To-Earnings vs Industry: BIOTEC-W1-R is expensive based on its Price-To-Earnings Ratio (10.8x) compared to the Asian Shipping industry average (8.6x).
Price to Earnings Ratio vs Fair Ratio
What is BIOTEC-W1-R's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
BIOTEC-W1-R PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
10.8x
Fair PE Ratio
n/a
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIOTEC-W1-R's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.